0001169245-22-000063.txt : 20220520
0001169245-22-000063.hdr.sgml : 20220520
20220520164523
ACCESSION NUMBER: 0001169245-22-000063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220519
FILED AS OF DATE: 20220520
DATE AS OF CHANGE: 20220520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sapir Alex
CENTRAL INDEX KEY: 0001709415
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38697
FILM NUMBER: 22948330
MAIL ADDRESS:
STREET 1: C/O DOVA PHARMACEUTICALS, INC.
STREET 2: 240 LEIGH FARM ROAD, SUITE 245
CITY: DURHAM
STATE: NC
ZIP: 27707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001169245
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030375697
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (610) 981-6500
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: Phase Biosciences Inc
DATE OF NAME CHANGE: 20061013
FORMER COMPANY:
FORMER CONFORMED NAME: DT BIOSCIENCES INC
DATE OF NAME CHANGE: 20020315
4
1
wf-form4_165307950359150.xml
FORM 4
X0306
4
2022-05-19
0
0001169245
PhaseBio Pharmaceuticals Inc
PHAS
0001709415
Sapir Alex
C/O PHASEBIO PHARMACEUTICALS, INC.
1 GREAT VALLEY PARKWAY, SUITE 30
MALVERN
PA
19355
1
0
0
0
Non-employee Director Stock Option (right to buy)
0.8419
2022-05-19
4
A
0
17500
0
A
2032-05-18
Common Stock
17500.0
17500
D
Restricted Stock Units
2022-05-19
4
A
0
3750
0
A
Common Stock
3750.0
3750
D
The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.
/s/ John P. Sharp, Attorney-in-fact
2022-05-20